About ADXS

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm Technology immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Biological Product (except Diagnostic) Manufacturing

ADXS is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.7 B 1.87292E+10 3,568 3568 0.0% 0 8 K 8020
IWC iShares Microcap ETF 916.2 M 9.16246E+08 1,452 1452 0.01% 0.0001 71 K 71168

Wait, Before You Leave...